Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Current Oncology (Toronto, Ont.)
|
October 27, 2022
Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada
Nimira Alimohamed, Simrun Grewal, Heidi S Wirtz, et al.
Urologic Oncology
|
December 15, 2024
Real-world survival and economic burden among patients with locally advanced or metastatic urothelial carcinoma in the United States
Ronald C Chen, Rupali Fuldeore, Alexandra Greatsinger, et al.
Current Oncology (Toronto, Ont.)
|
May 15, 2023
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)
Lisa Bloudek, Phoebe Wright, Caroline McKay, et al.
Clinical Genitourinary Cancer
|
December 11, 2024
Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab
Alicia K Morgans, Guru P Sonpavde, Vanessa Shih, et al.
BJU International
|
July 4, 2017
Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis
Marcus J Drake, Victor W Nitti, David A Ginsberg, et al.
The Patient
|
August 28, 2024
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
Andrea B Apolo, Christine Michaels-Igbokwe, Nicholas I Simon, et al.
European Urology
|
February 16, 2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial
Bradley McGregor, Peter H O'Donnell, Arjun Balar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
European Urology
|
February 28, 2024
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
Jonathan E Rosenberg, Ronac Mamtani, Guru P Sonpavde, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Current Oncology (Toronto, Ont.)
|
October 27, 2022
Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada
Nimira Alimohamed, Simrun Grewal, Heidi S Wirtz, et al.
Urologic Oncology
|
December 15, 2024
Real-world survival and economic burden among patients with locally advanced or metastatic urothelial carcinoma in the United States
Ronald C Chen, Rupali Fuldeore, Alexandra Greatsinger, et al.
Current Oncology (Toronto, Ont.)
|
May 15, 2023
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)
Lisa Bloudek, Phoebe Wright, Caroline McKay, et al.
Clinical Genitourinary Cancer
|
December 11, 2024
Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab
Alicia K Morgans, Guru P Sonpavde, Vanessa Shih, et al.
BJU International
|
July 4, 2017
Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis
Marcus J Drake, Victor W Nitti, David A Ginsberg, et al.
The Patient
|
August 28, 2024
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
Andrea B Apolo, Christine Michaels-Igbokwe, Nicholas I Simon, et al.
European Urology
|
February 16, 2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial
Bradley McGregor, Peter H O'Donnell, Arjun Balar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
European Urology
|
February 28, 2024
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
Jonathan E Rosenberg, Ronac Mamtani, Guru P Sonpavde, et al.
Page
of 4